Trials / Completed
CompletedNCT00684632
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo |
| DRUG | KW-2246 (fentanyl citrate) | KW-2246 (fentanyl citrate) |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-05-26
- Last updated
- 2020-08-28
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00684632. Inclusion in this directory is not an endorsement.